JeNaCell

Exit

JeNaCell produces biotechnologically generated nanocellulose (BNC) in an IP protected, continuous and automated production process: high quality innovative products for applications in medicine, cosmetics and more.

Press releases

HTGF Exit JeNaCell

Successful exit for High-Tech Gründerfonds – HTGF fund investor Evonik acquires biotech company JeNaCell Acquisition of JeNaCell expands Evonik’s portfolio of biomaterials used in medical technologyJeNaCell to realize full potential of its innovative technology and…
Read

Additional financing for JeNaCell: Investors once again back platform technology for the production of high-tech bio-material

The Jena biotech company successfully raises further venture capital in a Series A financing. The funds will be used for the expansion of its production capacity and the extension of its distribution network. JeNaCell is a specialist for biotechnologically produced nanocellulose and has developed a unique continuous…
Read

JeNaCell Receives Seed Financing from High-Tech Gründerfonds and STIFT

High-Tech Gründerfonds and STIFT are jointly investing €700,000 in JeNaCell GmbH. The capital will be used to build up automated production in the creation of a high-performance, high-tech biomaterial. The business idea of JeNaCell GmbH, a spin-off of the Friedrich Schiller University in Jena, Germany, is based…
Read

Info & Contact

PD Dr. Dana Kralisch
Web:
www.jenacell.com

Address

JeNaCell GmbH
Göschwitzer Str. 22
D-07745 Jena

In portfolio

14. Sep 2012 – 02. Aug 2021
Exit